ONCT News and Press, Oncternal Therapeutics Inc. From 07/20/20

Oncternal Therapeutics (NASDAQ: ONCT )   -8.7%  in pre-market, to offer ~2.6M shares at $2.3825/share, in a registered direct offering. More news on: Oncternal Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with existing institutional investors and other accredited investors, for ...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatme...

- Increasing planned enrollment of patients with MCL in ongoing CIRLL Phase 1/2 clinical trial of cirmtuzumab with ibrutinib based on encouraging data presented at ASCO 2020 - Meeting requested with FDA to discuss registration pathway for cirmtuzumab for patients with MCL Onctern...

Oncternal Therapeutics (NASDAQ: ONCT ) has entered into definitive agreements with several institutional investors for the purchase and sale of 1,943,636 common shares at a purchase price of $2.5725/share, in a registered direct offering priced at-the-market, for expected gross proceeds of...

Pyxus International (NYSE: PYX ) -26% . More news on: Pyxus International, Inc., Nano Dimension Ltd., Medigus Ltd., Stocks on the move, , Read more ...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,943...

 Gainers: Nano Dimension NNDM  +272% . More news on: ShiftPixy, Inc., Mercurity Fintech Holding Inc., Iterum Therapeutics plc, Stocks on the move, , Read more ...

58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8 months Cirmtuzumab continued to be well tolerated in this trial ...

Oncternal Therapeutics, Inc. (ONCT) Q1 2020 Earnings Conference Call May 7, 2020, 05:00 PM ET Company Participants Richard Vincent - CFO Jim Breitmeyer - President and CEO Frank Hsu - Chief Medical Officer Conference Call Participants Hartaj Singh - Oppenheimer Carl Byrne...